cyproterone acetate

P=N/A, N=52, Completed, University Hospital, Lille | Active, not recruiting --> Completed

Cyproterone acetate (CPA) is an antiandrogen that may be used in combination with estradiol in gender reaffirmation therapy...However, its effect appears to be delayed, indicating that cessation alone is suboptimal in cases causing significant mass effect and symptomatology. In such cases, early surgical intervention should be considered.

P=N/A, N=50, Recruiting, Medical University of Vienna | Trial primary completion date: Mar 2026 --> Mar 2027

P=N/A, N=500, Recruiting, IRCCS Azienda Ospedaliero-Universitaria di Bologna

P=N/A, N=30, Completed, Tel-Aviv Sourasky Medical Center

P=N/A, N=20, Active, not recruiting, Thai Red Cross AIDS Research Centre | Trial primary completion date: Oct 2023 --> Jan 2024

Our cases highlight the real-world risk of this likely underreported adverse effect and underscore the importance of clinician vigilance for neurological sequelae. We suggest using the lowest dose of CPA that maintains adequate androgen suppression, with consideration of alternative anti-androgens where appropriate.

P=N/A, N=50, Recruiting, Medical University of Vienna

P=N/A, N=960, Completed, Bayer | Active, not recruiting --> Completed

Finally, we show by exome analysis of breast tumors and meninges that hormone impregnation promotes breast tumor formation without additional somatic oncogenic mutation but is associated with an increased mutational burden on Pik3ca-mutant background. Taken together, these results tend to suggest a prominent role of Pik3ca mutations over hormone impregnation in meningioma tumorigenesis, the exact effect of the latter is still to be discovered.